A failed cholesterol trial at Novartis did more damage to BioNTech’s share price last week than anything coming out of Mainz. That disconnect says plenty about how biotech sentiment currently works — and how little it reflects the fundamentals of the company being sold.
The stock shed roughly 6.2% over the stretch through Friday, at one point touching 82.60 euros before steadying at 83.65 euros by the close. The trigger lay elsewhere entirely: Novartis disclosed in early September that Pelacarsen lowered Lp(a) levels but missed its primary composite endpoint of heart attacks, strokes and cardiovascular deaths. The fallout was swift and severe. Ionis Pharmaceuticals, which discovered and developed the compound before licensing it to Novartis, dropped about 10% on September 8. Amgen, whose competing olpasiran program now faces heightened scrutiny, fell $44.06 to $393.17 — its worst trading day since October 2000. Novartis itself gave up around 3% in Zurich.
BioNTech has no exposure to lipoprotein(a) therapies. It got dragged down anyway, a casualty of sector-wide jitters rather than any company-specific news.
A Pipeline That Argues the Other Way
What makes the selloff particularly hard to square is that BioNTech’s own news flow has been far from grim. Investor forums are buzzing about the oncology combination of BNT327 and BNT324 in small-cell lung cancer, where response rates are said to range from above 70% to north of 90%, depending on the treatment line. A Phase 3 trial of BNT327 against Keytruda in non-small-cell lung cancer is already running, and BNT323 could secure approval in China by 2026.
The caveats are real and worth stating plainly: mature overall survival data are still missing, and the commercial horizon for these programs stretches into the 2030s. Anyone hunting for a quick catalyst will come away disappointed. But that is precisely what separates BioNTech from a binary bet — these are medium-term oncology assets backed by promising early data, not an all-or-nothing event like Novartis’ Pelacarsen.
The company made that case on a bigger stage in August, presenting combination data for Pumitamig and Elfetabart Drozuntecan at the World Conference on Lung Cancer. It was a clear statement of where management sees the future. The broader industry is doing much the same: with the pandemic windfall over, mRNA and antibody developers are all hunting for the next major indication, and lung cancer has become the sector’s most contested battleground. Positioning, however, is not the same as proof. BMO Capital expects meaningful, supportive Pumitamig data no earlier than 2028.
The Old Business Is Eroding Faster Than the New One Can Grow
That timeline matters because the revenue base is shrinking. On August 4, BioNTech reported second-quarter 2026 results and cut its full-year sales guidance to EUR 1.6–1.9 billion from an earlier EUR 2.0–2.3 billion, citing weaker demand for its COVID vaccine and missed milestone payments. BMO responded in early September by downgrading the stock from “Outperform” to “Market Perform” and trimming its price target to $105. The broker pointed to a sharper-than-expected erosion of Comirnaty demand, the absence of relieving cancer-drug data until at least 2028, and softer expectations for the iNeST program.
Should investors sell immediately? Or is it worth buying BioNTech?
The pattern BMO described has not resolved since. Comirnaty, once the pandemic’s cash cow, is contracting faster than the oncology pipeline can offset. There was one operational win: in late August, Pfizer and BioNTech secured US regulatory approval for a Comirnaty shot adapted to the XFG variant for the 2026/2027 season. It is a step forward, but it does nothing to answer the structural question of how much longer COVID vaccines can generate meaningful revenue at all.
Setbacks have piled up on the pipeline side too. At the end of August, BioNTech and Genentech had to halt the Phase 2 BNT122-01 trial of Autogene Cevumeran in colorectal cancer patients with resected, ctDNA-positive tumors. An independent monitoring committee found a numerical imbalance in overall survival and saw no path forward. For a company that derives much of its value from individualized cancer therapies, that is more than a footnote. BioNTech stressed that a separate Phase 2 study, IMcode003, testing the same agent in pancreatic cancer, continues unchanged — yet the message between the lines is unmistakable: individualized mRNA cancer vaccines are proving more complicated than the euphoric post-pandemic years suggested.
Management has also flagged that it will clarify the future of its corporate sites by the end of September, without offering details so far. Whether that is routine administrative housekeeping or something more will become clear in due course.
What the Chart Is Actually Saying
At Friday’s 83.65 euros, the shares sit just below both their 50-day average of 84.08 euros and their 200-day average of 84.16 euros — a kind of equilibrium, arrived at after a 6.4% decline over seven days. The stock is about 21% below its 52-week high of 105.80 euros, set in January, though it has recovered 22% from its March low.
With a market capitalization of roughly EUR 20.85 billion and a negative P/E of -18.00, BioNTech remains a company whose valuation rests heavily on expectations for its oncology pipeline. The gap between the January peak and today’s level is not panic — it is a reflection of what the market has been digesting for months: a pharmaceutical company in transition, whose legacy business is eroding faster than the new one is becoming viable.
Is this the beginning of the end for mRNA enthusiasm, or merely a painful interim phase on the road to oncology maturity? The truth likely sits somewhere in between, and it will not come into focus until credible Pumitamig data arrive. Until then, BioNTech stays a company in waiting, its future tethered to study results still years away. Judging it solely on last week’s price action would mean badly underestimating the substance of that pipeline.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from September 13 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 13.
BioNTech: Buy or sell? Read more here...
